Core Insights - Zonsen PepLib Biotech Inc. has entered into a worldwide license agreement with Novartis for a peptide-based asset in radioligand therapies, granting Novartis exclusive rights for development and commercialization [1][2][3] Company Overview - Zonsen PepLib Biotech Inc. is an innovative biotechnology company focused on discovering and developing novel peptide-based therapeutics to improve treatment options globally, founded in September 2017 and headquartered in Zhuzhou, China [4] - The company employs over 200 people, with more than 80% engaged in research and development [4] Asset Development - The peptide asset has been developed internally by PepLib and is expected to complement Novartis' existing radioligand therapy portfolio, leveraging Novartis' capabilities to potentially provide new treatment options for patients [2][3] - Under the agreement, PepLib will receive an upfront payment of USD 50 million, with additional potential payments tied to development, regulatory, and sales milestones, as well as tiered royalties on future global net sales [3] Therapeutic Focus - PepLib has established a diverse suite of proprietary peptide libraries and discovery capabilities, primarily focusing on oncology and cardiometabolic diseases [5] - The company's platforms support multiple peptide-based modalities, including peptide radionuclide conjugates, peptide oligonucleotide conjugates, and peptide drug conjugates [5]